blocking ligand-induced phosphorylation of EGFR [4] . The addition of cetuximab to irinotecan has shown a higher response rate and longer progression-free survival compared with treatment with cetuximab alone in patients with irinotecan-refractory colorectal cancer [5] . These data suggest that cetuximab may overcome resistance to cytotoxic therapy. Subset analysis showed that previous treatment with oxaliplatin did not influence treatment outcome.
We designed the present trial to evaluate the efficacy of cetuximab plus oxaliplatin in patients having failed on an oxaliplatin-based regimen in first line, irinotecan-based regimen in second line, and cetuximab plus irinotecan in third line. A two-staged Simon accrual design was adopted for this phase II trial. Early discontinuation of the study was planned in the case of no response in the first 12 assessable patients. Patients were followed for tumor response and safety of treatment. The radiographic evaluation for tumor disease was performed every 2 months. Tumor response was evaluated according to the RECIST criteria and the side-effects were classified according to the WHO system. After progression with the third-line regimen all patients included in this trial were weekly treated with cetuximab (250 mg/m 2 ) plus oxaliplatin (35-40 mg/m 2 ) [6] . Although oxaliplatin is usually administered in combination with a fluoropyrimidine because of synergy, we decided to administer oxaliplatin as a single agent given the fact that all patients had already been pretreated with two fluoropyrimidine-containing regimens.
The median interval between the start of treatment and previous treatment with cetuximab plus irinotecan was 3 weeks (range 1-4); therefore, no loading dose of cetuximab was administered.
We included, in the first step of this trial 12 patients (colon nine, rectum three; males five, females seven; median age 66 years, range 37-79) whose disease had progressed during or within an oxaliplatin-based first-line chemotherapy (four patients treated with FOLFOX IV and eight with the XELOX regimen), an irinotecan-based second line regimen (FOLFIRI) and a third-line regimen with weekly cetuximab plus weekly irinotecan. Eight out of 12 (66.7%) patients showed clinical response after the oxaliplatin-based first-line chemotherapy. In addition, four patients (33.3%) exhibited partial response to the third-line therapy with cetuximab plus irinotecan. No objective clinical response was identified after the interim analysis planned according to the two-staged Simon accrual design. Only one patient showed a disease stabilization after the first 2 months of treatment, all the others showed, after the first 2 months of therapy, a disease progression according to the RECIST criteria. The median number of cetuximab + oxaliplatin infusions was six (range three to nine). Acne-like rash occurred in about 66.7% (eight of 12) of the patients and grade 3 or 4 toxic effects on the skin were observed in 16.7% (two of 12). The most common grade 3-4 non-cutaneous adverse events were asthenia (33.3%), neutropenia (16.7%) and diarrhoea (16.7%).
After the interim analysis, an early stopping of the trial was decided owing to the lack of any evidence of anticancer activity of the cross-over, as planned according to the accrual design.
The present trial is the first to investigate the efficacy of adding cetuximab to oxaliplatin in patients having progressed on oxaliplatin as well as on cetuximab plus irinotecan. The lack of response in our trial does not warrant further testing of this combination in this setting. 
